MAIA — MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: AMEX
• Employees: 13
• Website: https://www.MAIABiotech.com

Latest SEC filings for MAIA

• EFFECT — 2026-10-07
• S-3 — 2026-09-25
• S-3 — 2026-09-25
• S-3 — 2026-08-21
• S-3 — 2026-08-21
• SCHEDULE 13G/A — 2026-08-14
• 10-Q — 2026-08-10
• 8-K — 2026-05-22
• SCHEDULE 13G — 2026-05-15
• 424B5 — 2026-05-14

Latest MAIA news

• 2026-10-07 — MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer (globenewswire.com)
• 2026-10-01 — Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) (globenewswire.com)
• 2026-09-28 — MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest (youtube.com)

Abrir análisis completo

Educational tool only — not investment advice.